Kodiak Sciences stock soars on positive AMD trial data

Kodiak Sciences (KOD) shares surged 160.4% after positive Phase 3 DAYBREAK study results for wet AMD. Both drugs met key endpoints, and the company plans a Q4 2026 biologics license application. The move may also reflect short covering and elevated short interest.

Kodiak Sciences (KOD) stock surged over 130% after positive Phase 3 DAYBREAK study results for wet AMD treatments Zenkuda and Tabirafusp-ted. Both drugs showed non-inferior vision gains compared to Aflibercept. KOD's stock has risen over 440% in the past year, reaching an intraday high of $81.29.

Kodiak Sciences' shares surged 143% after its wet AMD treatments, Zenkuda and tabirafusp-ted, met primary endpoints in a Phase 3 trial, showing non-inferiority to aflibercept. The company plans regulatory filings by late 2026. Kodiak had $132M in cash at midyear with a $65M quarterly loss. Analysts' price targets range from $36 to $80.

The FDA approved AbbVie's Parkinson's pill, tavapadon, to be sold as Juvmo. The drug is part of its $8.7 billion acquisition of Cerevel Therapeutics. AbbVie expects over $5 billion in combined sales from its Parkinson's portfolio, though analysts caution uptake may be gradual due to Medicare coverage negotiations.

Kodiak Sciences Inc (KOD) closed at $32.35 on September 25, down 2.6%. Positive wet AMD trial data for Zenkuda was disclosed on September 28, alongside an Overweight rating from Cantor Fitzgerald. Technical indicators show bearish momentum but elevated volatility. The stock's future direction depends on how the market reacts to the clinical catalyst.

Kodiak Sciences (KOD) stock surged over 120% after positive test results for its eye drugs, Zenkuda and KSI-501, in treating wet age-related macular degeneration, positioning them as potential rivals to Regeneron's (REGN) Eylea.